α-Synuclein: Experimental Pathology

Cold Spring Harb Perspect Med. 2016 Sep 1;6(9):a024273. doi: 10.1101/cshperspect.a024273.

Abstract

α-Synuclein, which is present as a small, soluble, cytosolic protein in healthy subjects, is converted to amyloid-like fibrils in diseases such as Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). Bulk synthesis of purified α-synuclein has made it more convenient to study the nature of the normal protein and the mechanism of its conversion to an abnormal form in vitro and in vivo. Synthetic α-synuclein fibrils and pathological α-synuclein from diseased brains can act as triggers to convert normal α-synuclein to an abnormal form via prion-like mechanisms. In this article, we describe the experimental pathologies of α-synuclein both in vitro and in vivo in human and animal models. Prion-like spreading of abnormal α-synuclein from cell to cell can account for the progression of these α-synucleinopathies.

Publication types

  • Review

MeSH terms

  • Amyloid / metabolism*
  • Animals
  • Brain / metabolism
  • Brain / pathology*
  • Disease Models, Animal
  • Disease Progression
  • Humans
  • Lewy Body Disease / pathology
  • Mice
  • Multiple System Atrophy / pathology
  • Parkinson Disease / pathology
  • alpha-Synuclein / metabolism*

Substances

  • Amyloid
  • alpha-Synuclein